Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Micha

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Cancer|June 1, 1989
Radical hysterectomy and tailored postoperative radiation therapy in the management of bulky stage 1B cervical cancerM A Rettenmaier, D M Casanova, J P Micha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2007
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancerJ P Micha, B H Goldstein, M A Rettenmaier, et al.
Gynecologic Oncology|November 1, 1986
Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatinJ A Stratton, P R Kucera, M A Rettenmaier, et al.
Gynecologic Oncology|December 6, 2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneumJ V Brown, W A Peters, M A Rettenmaier, et al.
Antiviral Research|November 1, 1988
Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapyR C Reichman, J P Micha, P K Weck, et al.
Gynecologic Oncology|September 23, 2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Cancer|June 1, 1989
Radical hysterectomy and tailored postoperative radiation therapy in the management of bulky stage 1B cervical cancerM A Rettenmaier, D M Casanova, J P Micha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2007
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancerJ P Micha, B H Goldstein, M A Rettenmaier, et al.
Gynecologic Oncology|November 1, 1986
Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatinJ A Stratton, P R Kucera, M A Rettenmaier, et al.
Gynecologic Oncology|December 6, 2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneumJ V Brown, W A Peters, M A Rettenmaier, et al.
Antiviral Research|November 1, 1988
Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapyR C Reichman, J P Micha, P K Weck, et al.
Gynecologic Oncology|September 23, 2017
A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancerG Rustin, I Vergote, J P Micha, et al.
Pageof 4